AEROLONE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AEROLONE (AEROLONE).
Selective beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via adenylate cyclase activation.
| Metabolism | Primarily metabolized by CYP3A4 and to a lesser extent CYP2D6, with conjugation to inactive metabolites. |
| Excretion | Primarily renal excretion of unchanged drug (approximately 65%) and hepatic metabolism (35%), with metabolites excreted in urine and feces. Biliary/fecal elimination accounts for <10%. |
| Half-life | Terminal elimination half-life is approximately 12-15 hours in adults; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | Approximately 88% bound, primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 3.5-5.0 L/kg, indicating extensive extravascular distribution and tissue binding. |
| Bioavailability | Oral: 35-50% (first-pass metabolism); Inhalation: 15-30% (dependent on device and technique); Intravenous: 100%. |
| Onset of Action | Oral: 30-60 minutes; Inhalation: 5-15 minutes; Intravenous: 2-5 minutes. |
| Duration of Action | Oral: 8-12 hours; Inhalation: 4-6 hours; Intravenous: 4-8 hours. Duration is dose-dependent and may be shorter with single doses. |
AEROLONE is not a recognized drug; no standard dosing available.
| Dosage form | SOLUTION |
| Renal impairment | No data; not applicable. |
| Liver impairment | No data; not applicable. |
| Pediatric use | No data; not applicable. |
| Geriatric use | No data; not applicable. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AEROLONE (AEROLONE).
| Breastfeeding | Unknown whether fluticasone propionate is excreted in human breast milk. Other corticosteroids are excreted in breast milk in low amounts, and inhaled doses result in negligible systemic levels, predicting unlikely significant infant exposure. M/P ratio not determined. Caution advised; weigh risk of maternal obstructive airway disease exacerbation against potential infant risks (adrenal suppression, growth retardation). |
| Teratogenic Risk | No evidence of teratogenicity in animal studies at doses up to 10 mg/kg/day (approximately 120 times the maximum recommended human daily inhaled dose). In humans, no controlled studies exist; however, data from postmarketing reports do not suggest an increased risk of structural anomalies. First trimester: limited data preclude definitive risk assessment, but no pattern of major birth defects has emerged. Second and third trimesters: no known fetal harm from inhaled doses; however, potential for fetal adrenal suppression with prolonged high-dose systemic exposure. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to arformoterol or any component of the formulation"]
| Precautions | ["Paradoxical bronchospasm","Cardiovascular effects (e.g., increased heart rate, QT prolongation)","Hypokalemia","Hyperglycemia"] |
| Food/Dietary | No significant food interactions. Avoid grapefruit juice as it may affect metabolism of the corticosteroid component. |
| Clinical Pearls | AEROLONE is a combination inhaler containing an inhaled corticosteroid (fluticasone propionate) and a long-acting beta2-agonist (salmeterol). Advise patients to rinse mouth with water after each use to reduce risk of oral candidiasis. Not for acute bronchospasm; use a rescue inhaler (short-acting beta agonist) as needed. Monitor for increased heart rate, palpitations, or tremor. Do not stop abruptly; taper dose under medical supervision if discontinuing. |
Loading safety data…
| Fetal Monitoring | Monitor maternal forced expiratory volume in 1 second (FEV1) and symptom control. No specific fetal monitoring required beyond standard prenatal care. In cases of prolonged high-dose use, consider neonatal monitoring for adrenal suppression (e.g., transient adrenal insufficiency signs like lethargy, feeding difficulty). |
| Fertility Effects | No known impairment of male or female fertility based on limited animal studies (no effect on fertility in rats at doses up to 50 mcg/kg/day). In humans, no data suggest adverse effects on fertility from inhaled fluticasone. |
| Patient Advice | Use AEROLONE exactly as prescribed; do not exceed recommended dose. · Rinse your mouth with water after each use (do not swallow) to prevent thrush. · This medication is not for sudden breathing problems; always keep your rescue inhaler (e.g., albuterol) with you. · Do not stop using this medicine without talking to your doctor, as stopping suddenly may worsen your breathing. · Seek immediate medical help if you experience worsening asthma, chest pain, or allergic reaction. |